gsk201202106k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 

 
 
 



 
 

 

 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
 
I give below details of changes in the interests of a Person Discharging Managerial Responsibility and her Connected Person in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary shares") on 10 February 2012:
 
 
Mrs V A Whyte
Exercise of an SAYE share option to purchase 1,009 Ordinary shares, granted on 1 December 2008 under GSK's all employee Sharesave Plan at a price of £9.51 per share.
   
 
The transfer by way of gift of 1631 Ordinary shares to her connected person, Mr I Whyte.
 
 
 
The Company and the above mentioned persons were advised of these transactions on 10 February 2012.
 
This notification relates to transactions notified in accordance with Disclosure Rule 3.1.4R(1)(a) and (c).
 
 
V A Whyte
Company Secretary
 
10 February 2012
 

 

 
 

 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 10, 2012
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc